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Background. Streptococcus pneumoniae infections have become increasingly complicated and costly to treat with the spread of antibiotic resistance. We evaluated the relationship between antibiotic prescribing and nonsusceptibility among invasive pneumococcal disease (IPD) isolates.
Methods. Outpatient antibiotic prescription data for penicillins, cephalosporins, macrolides, and trimethoprim-sulfamethoxazole were abstracted from the IMS Health Xponent database to calculate the annual number of prescriptions per capita. We analyzed IPD data from 7 of the Centers for Disease Control and Prevention's Active Bacterial Core surveillance sites (population, 18.6 million) for which data were available for the entire time period under study (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) . Logistic regression models were used to assess whether sites with high antibiotic prescribing rates had a high proportion of nonsusceptible and serotype 19A IPD.
Results. Yearly prescribing rates during the period 1996-2003 for children ,5 years of age decreased by 37%, from 4.23 to 2.68 prescriptions per capita per year (P , .001), and those for persons $5 years of age decreased by 42%, from 0.98 to 0.57 prescriptions per capita per year (P , .001); increases in azithromycin prescribing were noted for both groups. Sites with high rates of antibiotic prescribing had a higher proportion of IPD nonsusceptibility than did low-prescribing sites (P 5 .003 for penicillin, P , .001 for every other antibiotic class). Cephalosporin and macrolide prescribing were associated with penicillin and multidrug nonsusceptibility and serotype 19A IPD (P , .001).
Conclusions. In sites where antibiotic prescribing is high, the proportion of nonsusceptible IPD is also high, suggesting that local prescribing practices contribute to local resistance patterns. Cephalosporins and macrolides seem to be selecting for penicillin-and multidrug-resistant pneumococci, as well as serotype 19A IPD. Antibiotic use is a major factor contributing to the spread of antibiotic resistance; strategies to reduce antibiotic resistance should continue to include judicious use of antibiotics.
Disease caused by Streptococcus pneumoniae, the leading cause of severe bacterial respiratory illness and community-acquired invasive disease, has become increasingly complicated and costly to treat with the spread of antibiotic resistance [1] [2] [3] . An understanding of the factors that are promoting resistance is important to identify potential interventions. On an individual level, antibiotic use has been shown to be an important contributing factor in the development of pneumococcal resistance [4, 5] . Recent antibiotic treatment is a risk factor for infection or colonization with penicillinresistant pneumococci; persons treated with azithromycin or clarithromycin in a randomized, double-blind study had much higher pharyngeal carriage rates of macrolide-resistant streptococci than did persons who did not receive antibiotics [6] . In addition, antibiotic use by individuals appears to increase the probability that other members of the community will be colonized and infected by resistant organisms [5] [6] [7] .
There is also evidence that a high volume of antibiotic use on a national level can lead to higher rates of antibiotic resistance. Monitoring of S. pneumoniae resistance through the European Antimicrobial Resistance Surveillance System reveals that European countries with higher outpatient sales of b-lactams and macrolides also have a higher proportion of penicillinnonsusceptible S. pneumoniae isolates [8, 9] . Analyses comparing antimicrobial usage in Europe during the period 1998-2004 and antimicrobial resistance rates during the period 2004-2005 show a significant association between antimicrobial use and S. pneumoniae resistance to b-lactams, erythromycin, tetracycline, and multiple drugs [10] .
Whereas reductions in the rates of invasive pneumococcal disease (IPD) (susceptible and nonsusceptible) have been documented in the United States since the introduction of pneumococcal conjugate vaccine (Prevnar, PCV7) in 2000, there has been a much smaller, albeit substantial, increase in the incidence of antibiotic-resistant, nonvaccine-type disease [11] [12] [13] . The nonvaccine serotype 19A has been shown to be highly resistant, a characteristic that may have favored its emergence. Although vaccine introduction may have contributed to the expansion of nonsusceptible clones of 19A, there is evidence to suggest that antibiotic pressure may have also played a role [14, 15] . However, the relationship between antimicrobial use and S. pneumoniae antimicrobial resistance is not well defined in the United States. We conducted analyses to assess patterns in antibiotic prescribing and antibiotic-resistant IPD and to evaluate the hypothesis that nonsusceptible IPD increases as antibiotic prescriptions increase.
METHODS
Systemic antibiotic prescriptions dispensed according to postal code during the period 1996-2003 were extracted from the IMS Health Xponent prescription database, which contains 70% of all outpatient prescriptions in the United States projected to 100% coverage of all prescription activity using a patented projection methodology (US patent numbers 7174304 and 5420786). These data represent a statistically valid projection of all prescriptions, across all payers. Retail pharmacies and federal government and nongovernmental mail-service pharmacies were the sources for outpatient antimicrobial prescription data for oral penicillins, cephalosporins, macrolides (includes azalides), and trimethoprim-sulfamethoxazole. Although data on antimicrobial prescriptions of fluoroquinolones were available, early analyses revealed that the number of fluoroquinolone-resistant IPD isolates was small, so this class of antibiotics was excluded from the analyses. Prescriptions per capita, by site and class, were considered a proxy for the frequency of antibiotic use. Prescriptions of liquid, syrup, and chewable antimicrobial formulations were assumed to be representative of prescriptions for children ,5 years of age. Solid antimicrobial formulation sales were assumed to be representative of prescriptions for persons $5 years of age.
We analyzed data from the Centers for Disease Control and Prevention (CDC)'s Active Bacterial Core surveillance (ABCs), an active, population-based system that tracks IPD. ABCs counties in Connecticut, Georgia, Maryland, Minnesota, New York, Oregon, and Tennessee were selected for the analyses (population, 18.6 million), because IPD data and antibiotic prescription data were available for the entire time period under study (January 1996 through December 2003) in those areas. ABCs defined a case of IPD as an illness in which S. pneumoniae was isolated from a normally sterile site, such as blood, cerebrospinal fluid, or pleural fluid. Additional details regarding ABCs have been described previously (www.cdc.gov/abcs) [16] .
Isolates underwent susceptibility testing by means of broth microdilution at the CDC, the Minnesota Department of Health Laboratory, or the University of Texas Health Science Center Laboratory. Antibiotic susceptibility was defined according to break points for minimal inhibitory concentrations (MICs) determined by the Clinical and Laboratory Standards Institute [17] . Isolate break points for penicillin were defined as susceptible (#0.06 lg/mL), intermediate (0.12-1 lg/mL), or resistant ($2 lg/mL). The penicillin break points for S. pneumoniae were based on attainable bioavailability of oral penicillins. Because we did not differentiate between invasive clinical syndromes and we wanted a marker for the epidemiological analysis of penicillin resistance following oral use, we applied the oral break points for all isolates. Penicillin nonsusceptibility implies nonsusceptibility to oral cephalosporins due to a shared resistance mechanism; therefore, we do not present cephalosporin nonsusceptibility separately. Isolates recorded as intermediately susceptible or resistant were categorized as nonsusceptible for all antibiotic classes. The proportions (percentages of IPD isolates nonsusceptible to penicillins, macrolides, and trimethoprim-sulfamethoxazole) were evaluated for the 7 ABCs sites and 2 age groups. Multidrug nonsusceptibility was defined as nonsusceptibility to penicillins, macrolides, and trimethoprim-sulfamethoxazole.
We assessed trends in antibiotic prescriptions and the proportion of nonsusceptible IPD and evaluated the relationship between antimicrobial use and S. pneumoniae resistance. Antibiotic prescription rates for 1996-2003 were expressed as the number of prescriptions per capita using population estimates for each site from the US Census Bureau for each respective year and age group. To investigate the relationship between the proportion of nonsusceptible IPD and antibiotic use, the 7 ABCs sites were classified into high-prescribing and low-prescribing sites according to the median antibiotic prescription rate for each antibiotic class according to the entire time period. Sites with an antibiotic prescription rate greater than or equal to the median for a particular antibiotic class were considered high prescribing, whereas sites below the median were considered low prescribing. To account for small numbers of IPD cases, monthly IPD data were aggregated into 6-month periods (April-September and October-March) each year plus 2 periods of 3 months in 1996 and 2003 to complete the analyses for those calendar years, resulting in 17 periods total. The months of October-March were defined as the fall-winter season, and the months April-September were defined as the spring-summer season. Antibiotic prescription data were aggregated using the same 17 periods. We defined the pre-PCV7 period as 1996-1999 and the post-PCV7 period as 2000-2003. Logistic regression models were used to assess the association between antibiotic use and the proportion of nonsusceptible IPD, controlling for season, because of higher disease rates during the winter months. Logistic regression models were also used to assess the association between antibiotic use and the proportion of serotype 19A IPD among all IPD isolates. Separate models were developed for the different drug classes. Friedman tests, which can be regarded as a nonparametric counterpart to the paired Student's t test, were also used to compare the proportion of nonsusceptible IPD between high-prescription and lowprescription states over the 17 periods. We completed regression analyses for all ages and each drug class. In addition, monthly prescriptions of all antibiotics and each class and the corresponding monthly proportions of nonsusceptible IPD were used to calculate the Pearson correlation coefficient (r). SAS, version 9.2 (SAS Institute), was used for data analyses.
RESULTS
The mean number of antibiotic prescriptions (penicillins, cephalosporins, macrolides, and trimethoprim-sulfamethoxazole) dispensed during the period 1996-2003 was 0.91 prescriptions per capita per year (range, 0.61-1.26 prescriptions per capita per year). Antibiotic prescriptions of penicillins, cephalosporins, macrolides, and trimethoprim-sulfamethoxazole decreased over this time period in the outpatient setting for children ,5 years of age and persons $5 years of age (Figures 1 and 2) . The total number of prescriptions for children Increases in sales of azithromycin were also observed for persons $5 years of age from 0.05 prescriptions per capita in 1996 to 0.11 in 2003, an increase of 139% (P , .001).
Regional differences in prescribing rates were observed during the period. In the high-prescribing month of December, for example, the highest-prescribing site reported a mean 6 standard deviation of 0.13 6 0.04 prescriptions per capita, whereas the lowest-prescribing site reported 0.06 6 0.02 prescriptions per capita. Sites that were categorized as high prescribing for 1 class of antibiotics were not necessarily categorized as high prescribing for other classes. Across all months and years, the regional differences in prescribing were significant (P , .001). Tennessee consistently had the highest prescribing rates, whereas Oregon, with the exception of trimethoprim-sulfamethoxazole, had the lowest prescribing rates.
Cases of IPD between 1996 and 2003 totaled 25,412, with a range of 2726-3771 among sites. Cases of nonsusceptible IPD (nonsusceptible to $1 antibiotic class) between 1996 and 2003 totaled 8900, with a range of 469-2565 cases among sites. In young children, the incidence of nonsusceptible IPD decreased from 28.72 cases per 100,000 children aged ,5 years in 1996 to 8.08 cases per 100,000 children aged ,5 years in 2003, a decrease of 72% (P , .001). The incidence of nonsusceptible IPD decreased from 4.83 cases per 100,000 persons A comparison of sites with high antibiotic prescription rates to sites with low rates of prescription for the same antibiotic class revealed a consistent relationship between higher prescription rates and higher proportions of nonsusceptibility to the respective antibiotic class (Table 1) . This relationship was observed for all antibiotic classes that we evaluated with the logistic regression model. Of note, cephalosporin and macrolide prescribing were both highly associated with penicillin resistance with odds ratios of 1.91, (95% confidence interval (95% CI 1.80-2.03, both P , .001), compared with an odds ratio of 1.09 for penicillin prescribing (95% CI 1.03-1.16 P 5 .003). Cephalosporin and macrolide prescribing were also both highly associated with multidrug nonsusceptibility, with odds ratios of 3.13 (95% CI 2.88-3.39, both P , .001). Greater numbers of antibiotic prescriptions per month correlated positively (r 5 0.19, P , .001) with an increased monthly proportion of penicillin-nonsusceptible isolates. A positive correlation was also observed for prescriptions and nonsusceptibility to individual antibiotic classes.
A comparison of sites with high antibiotic prescription rates to sites with low rates of prescriptions of the same antibiotic class ( Table 2) revealed that cephalosporin and macrolide prescriptions wereboth associated with a higher proportion of serotype 19A IPD, with odds ratios of 1.43 (95% CI 1.25-1.64 both P , .001). This association between cephalosporin and macrolide prescribing and 19A IPD was most marked during the period 2000-2003, with odds ratios of 1.67 for both (95% CI 1.41-1.98 both P , .001). Penicillin and trimethoprim-sulfamethoxazole prescriptions were not associated with increased proportions of 19A IPD.
DISCUSSION
Our analyses support the hypothesis that higher rates of prescribing and use of antibiotics correspond to a higher prevalence of nonsusceptible IPD. In geographic areas where antibiotic prescription rates are higher, the proportion of nonsusceptible IPD is also higher, suggesting that local variation in prescribing contributes to local resistance patterns. Mathematical transmission modeling has previously suggested that the intensity of selection for resistance (ie, antibiotic use), reflected by differences between the proportions of resistance within individual serotypes, rather than differences in the prevalence of resistant clones, accounts for geographic diversity in S. pneumoniae resistance [18] .
Dramatic reductions in the incidence of IPD observed after PCV7 introduction in the United States have been somewhat offset by increases in the incidence of serotype 19A IPD, and these changes seem to have been sustained [19] . Although we are unable to examine how PCV7 contributed to this increase, our results suggest that antibiotic use played an important role. Sites with high rates of cephalosporin and macrolide prescribing had a higher proportion of disease caused by the frequently multidrug-resistant serotype 19A than did low-prescribing sites, especially during the post-PCV7 period. Our findings are supported by Dagan et al, who reported increases in acute otitis [20] . The authors also report that increases in 19A disease have been confined to countries where antibiotic use is high. Whereas outpatient antibiotic use in the United States has decreased for both adults and children between 1996 and 2003, our study and others report an increase in prescribing of newer, broad-spectrum agents and of azithromycin in particular [21, 22] . The increase in azithromycin prescribing is likely explained by effective marketing strategies and convenient dosing due to the drug's long half-life [23] , a characteristic that promotes resistance. Several studies have provided evidence for a relationship between macrolide use and S. pneumoniae resistance. Macrolide exposure leads to emergence of macrolide resistance on the individual level, and countries with higher outpatient sales of macrolides have more macrolide-resistant pneumococci [8, 24, 25] . A 2001 study showed that increased macrolide use in the United States from 1995 to 1999 coincided with a doubling of the proportion of macrolide-resistant pneumococci [26] , and further increases in macrolide use since 1999 have likely contributed to the increase in the proportion of macrolideresistant pneumococci [27] . The increase in azithromycin use is concerning given our findings that macrolide (and cephalosporin) use appears to be contributing more to penicillin and multidrug resistance than does penicillin use. Data from other studies also suggest that azithromycin may be the primary driver of not only macrolide but also penicillin and multidrug resistance among S. pneumoniae [28] [29] [30] [31] [32] [33] . In addition, we hypothesize that macrolide resistance likely increases the opportunity for the strain to remain in circulation, resulting in more exposure to b-lactams. Although the changes that cause b-lactam and macrolide resistance in the bacterial chromosome are independent events, the accumulation of multiple resistance determinants in the pneumococcus allows 1 class of drug to select multiply resistant strains [18] .
Although most S. pneumoniae strains remain responsive to penicillin treatment, especially if high intravenous doses are used, S. pneumoniae strains with an intermediate penicillin MIC between 0.12 and 1.0 lg/mL are often resistant to oral cephalosporins [34] . The persistence of pneumococci in the upper respiratory tract following exposure to poorly active oral cephalosporins [34] may explain why cephalosporin use appears in our study to influence the frequency of penicillin nonsusceptibility more than penicillin use.
Although we report logistic regression analyses for resistance to individual antibiotic classes, we were unable to fully evaluate the specific antibiotic class effects on isolates that were resistant to just 1 antibiotic class; most isolates were resistant to multiple classes of antibiotics. Furthermore, our analyses were specific to IPD and did not incorporate noninvasive isolates, which might have led to different results. Although data on fluoroquinolone prescriptions were available, early analyses revealed few fluoroquinolone-resistant IPD isolates. We excluded this class of antibiotics from the analyses as a result of small isolate numbers and rare fluoroquinolone use in young children. We also made assumptions that antibiotic prescriptions of liquid, syrup, and chewable antibiotics corresponded to use for children ,5 years of age and solid antibiotics corresponded to use in individuals $5 years of age, but this definition has been commonly used previously [35] . The most meaningful approach to measure antibiotic use and the effect on antibiotic resistance remains unclear and likely varies by pathogen. Our data set did not contain information about dose and duration of therapy, so we were unable to take these factors into consideration. A comparison of outpatient antibiotic use in the United States and 27 European countries in 2004 revealed that antibiotic use varies widely by country, but only 3 European countries exceeded the United States in overall use [36] . Our data analyses suggest that even in a single country, such as the United States, where there are uniform guidelines for treatment and prescribing, antibiotic use varies substantially and increased antibiotic prescribing in the community is associated with increased prevalence of resistant pneumococcal disease. Marked variation in outpatient antibiotic prescribing in the United States has also been described according to health insurance plan and region [37] . What remains unclear are the factors that are contributing to the geographic differences in prescribing that we observed.
The introduction of PCV7 resulted in a dramatic decline in the incidence of nonsusceptible pneumococcal disease [38] , and with the introduction of expanded-valent pneumococcal conjugate vaccines, there is promise for further reductions in antibiotic-resistant pneumococcal disease. Despite declines in antibiotic prescribing, antibiotic use remains common for infections that usually do not require antibiotic therapy [21] . Therefore, judicious use of antibiotics and selection of the Sites were classified as high prescribing or low prescribing according to the median antibiotic prescription rate for each antibiotic class.
Abbreviations: OR, odds ratio. 95% CI, 95% confidence interval. a The pre-pneumococcal conjugate vaccine 7 (PCV7) period is defined as 1996-1999, and the post-PCV7 period is 2000-2003. b Total number of serotyped IPD isolates for the respective period.
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Notes

